RCEL
AVITA Medical, Inc.
+0.46 (+4.45%)10.92USD96.4K成交股數338M市值–本益比(近四季)4.5股價營收比+17.8%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 21.7M+17% | 19.3M+5% | 17.1M-13% | 18.4M+21% | 18.5M+67% | 18.4M+35% | 19.5M+66% | 15.2M+44% | 11.1M | 13.6M | 11.8M | 10.6M |
| 營業成本 | 3.9M | 3.5M | 3.2M | 3.5M | 2.8M | 2.3M | 3.2M | 2.1M | 1.5M | 2.1M | 2.2M | 1.7M |
| 毛利 | 17.8M+13% | 15.7M-2% | 13.9M-15% | 14.9M+14% | 15.7M+63% | 16.1M+40% | 16.4M+71% | 13.1M+47% | 9.6M | 11.5M | 9.5M | 8.9M |
| 毛利率 | 81.9% | 81.7% | 81.3% | 81.2% | 84.7% | 87.6% | 83.7% | 86.1% | 86.4% | 84.5% | 81.2% | 84.2% |
| 研發費用 | 5.1M | 5.6M | 3.7M | 5.1M | 6.3M | 4.9M | 5.4M | 4.9M | 5.2M | 4.4M | 5.1M | 4.6M |
| 銷售管理費用 | 6.0M | 6.1M | 7.2M | 6.7M | 6.4M | 7.1M | 9.6M | 7.5M | 9.0M | 6.1M | 6.2M | 8.3M |
| 營業利益 | −6.9M-42% | −8.8M-12% | −9.2M-34% | −11.1M-29% | −11.8M-31% | −10.0M+7% | −13.8M+24% | −15.6M+58% | −17.2M | −9.3M | −11.2M | −9.9M |
| 營業利益率 | -31.6% | -45.7% | -53.6% | -60.5% | -63.9% | -54.1% | -70.6% | -102.8% | -155.0% | -68.2% | -95.0% | -93.9% |
| 稅後淨利 | −7.7M-45% | −10.6M-8% | −13.2M-19% | −9.9M-36% | −13.9M-26% | −11.6M+33% | −16.2M+56% | −15.4M+67% | −18.7M | −8.7M | −10.4M | −9.2M |
| 淨利率 | -35.3% | -55.1% | -77.3% | -53.9% | -74.9% | -63.0% | -82.9% | -101.3% | -168.0% | -63.8% | -88.4% | -87.4% |
| 稀釋 EPS | -0.25-53% | -0.35-20% | -0.46-26% | -0.38-37% | -0.53-27% | -0.44+29% | -0.62+51% | -0.60+62% | -0.73 | -0.34 | -0.41 | -0.37 |
| 稀釋股數 | 30.7M | 30.5M | 28.4M | 26.4M | 26.3M | 25.9M | 26.0M | 25.8M | 25.6M | 25.4M | 25.2M | 25.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 9.1M | 8.3M | 15.4M | 12.2M | 14.9M | 14.1M | 18.6M | 17.5M | 17.0M | 50.9M | 37.5M | 28.1M |
| 應收帳款 | 9.9M | 9.9M | 9.0M | 11.3M | 9.1M | 11.8M | 10.3M | 8.7M | 11.8M | 5.9M | 5.8M | 4.5M |
| 存貨 | 5.3M | 6.1M | 7.2M | 7.5M | 8.4M | 7.3M | 6.2M | 6.7M | 7.2M | 4.4M | 3.1M | 2.8M |
| 總資產 | 47.8M | 51.5M | 63.7M | 58.1M | 69.6M | 79.7M | 81.1M | 87.8M | 97.4M | 81.0M | 86.3M | 92.6M |
| 有息負債 | – | – | 0.00 | 42.2M | 41.5M | 42.2M | 42.5M | 41.0M | 41.3M | – | – | – |
| 總負債 | 75.6M | 74.7M | 70.4M | 71.0M | 74.1M | 75.0M | 68.6M | 63.5M | 64.0M | 17.4M | 16.5M | 14.3M |
| 股東權益 | −27.8M | −23.2M | −6.7M | −12.9M | −4.6M | 4.5M | 12.2M | 23.9M | 32.6M | 63.0M | 68.6M | 77.6M |
| 負債比 | 158.3% | 144.9% | 110.5% | 122.1% | 106.5% | 94.0% | 84.6% | 72.3% | 65.7% | 21.5% | 19.1% | 15.4% |
| 淨現金(現金 − 有息負債) | – | – | 15.4M | −30.0M | −26.6M | −28.2M | −23.9M | −23.5M | −24.4M | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −10.1M | – | – | −10.3M-51% | – | – | – | −20.9M | – | – | −9.1M |
| 資本支出 | – | 19K | – | – | 221K | – | – | – | 1.1M | – | – | 284K |
| 自由現金流 | – | −10.1M | – | – | −10.5M-52% | – | – | – | −22.0M | – | – | −9.4M |
| 折舊攤銷 | – | 627K | – | – | 521K | – | – | – | 203K | – | – | 135K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -52.4% | – | – | -56.9% | – | – | – | -198.2% | – | – | -88.7% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 71.6M
| 美國 | 68.8M | 96.1% | +10.7% |
|---|---|---|---|
| 日本 | 2.1M | 2.9% | +45.9% |
| 英國 | 486K | 0.7% | +148.0% |
| 澳洲 | 200K | 0.3% | -35.9% |
| European Union | 49K | 0.1% | -68.4% |
主要客戶2025 年度 · 71.6M
| Commercial Sales | 71.4M | 99.8% | +11.6% |
|---|---|---|---|
| Revenue For Right Of First Access | 139K | 0.2% | -28.7% |
| Deferred Commercial Revenue Recognized | 33K | 0.0% | 0.0% |
產品／服務2025 年度 · 41.8M
| Recell Go Preparation Kit | 35.8M | 85.6% | +104.6% |
|---|---|---|---|
| Permeaderm | 6.0M | 14.4% | – |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 71.6M | +11.5% | −48.6M | -67.8% | -1.74 | −32.2M |
| FY2024 | 64.3M | +28.1% | −61.8M | -96.3% | -2.39 | −58.1M |
| FY2023 | 50.1M | +45.7% | −35.4M | -70.6% | -1.40 | −39.4M |
| FY2022 | 34.4M | +17.8% | −26.7M | -77.5% | 1.07 | −19.5M |
| FY2021 | 29.2M | +104.9% | −26.6M | -90.9% | 1.17 | −26.8M |
| FY2020 | 14.3M | +160.6% | −42.0M | -294.7% | 2.07 | −23.3M |
| FY2019 | 5.5M | – | −25.1M | -458.6% | 1.56 | −20.3M |